title: Endocrine regulation of airway contractility is overlooked.
abstract: Asthma is a prevalent respiratory disorder triggered by a variety of inhaled environmental factors, such as allergens, viruses, and pollutants. Asthma is characterized by an elevated activation of the smooth muscle surrounding the airways, as well as a propensity of the airways to narrow excessively in response to a spasmogen (i.e. contractile agonist), a feature called airway hyperresponsiveness. The level of airway smooth muscle (ASM) activation is putatively controlled by mediators released in its vicinity. In asthma, many mediators that affect ASM contractility originate from inflammatory cells that are mobilized into the airways, such as eosinophils. However, mounting evidence indicates that mediators released by remote organs can also influence the level of activation of ASM, as well as its level of responsiveness to spasmogens and relaxant agonists. These remote mediators are transported through circulating blood to act either directly on ASM or indirectly via the nervous system by tuning the level of cholinergic activation of ASM. Indeed, mediators generated from diverse organs, including the adrenals, pancreas, adipose tissue, gonads, heart, intestines, and stomach, affect the contractility of ASM. Together, these results suggest that, apart from a paracrine mode of regulation, ASM is subjected to an endocrine mode of regulation. The results also imply that defects in organs other than the lungs can contribute to asthma symptoms and severity. In this review, I suggest that the endocrine mode of regulation of ASM contractility is overlooked.
authors.affiliation: Institut Universitaire de Cardiologie et de Pneumologie de QuébecUniversité Laval, Québec, Québec, Canada G1V 4G5 ynuk.bosse@criucpq.ulaval.ca.
authors.forename: Ynuk
authors.initials: Y
authors.lastname: Bossé
mesh_terms: D000222:Adaptation, Physiological; D052242:Adiponectin / Q000502:physiology; D000728:Androgens / Q000502:physiology; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000494:pharmacology; D003687:Dehydroepiandrosterone / Q000502:physiology; D004837:Epinephrine / Q000502:physiology; D004967:Estrogens / Q000502:physiology; D005260:Female; D005337:Fibrin / Q000502:physiology; D019886:Gastrin-Releasing Peptide / Q000502:physiology; D005768:Gastrointestinal Hormones / Q000502:physiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000502:physiology; D020738:Leptin / Q000502:physiology; D008168:Lung / Q000187:drug effects*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D045265:Natriuretic Peptides / Q000502:physiology; D011374:Progesterone / Q000502:physiology; D012143:Respiratory Physiological Phenomena / Q000187:drug effects; D012137:Respiratory System / Q000187:drug effects*; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D013963:Thyroid Hormones / Q000502:physiology; D014568:Urokinase-Type Plasminogen Activator / Q000502:physiology
chemical_list: D052242:Adiponectin; D000728:Androgens; D001993:Bronchodilator Agents; D004967:Estrogens; D005768:Gastrointestinal Hormones; D005938:Glucocorticoids; D007328:Insulin; D020738:Leptin; D045265:Natriuretic Peptides; D013963:Thyroid Hormones; C003237:proxyphylline; C072685:guanylin; C084362:uroguanylin; D003687:Dehydroepiandrosterone; D011374:Progesterone; D019886:Gastrin-Releasing Peptide; D005337:Fibrin; D013806:Theophylline; D014568:Urokinase-Type Plasminogen Activator; D004837:Epinephrine
keywords: airway hyperresponsiveness; airway smooth muscle; asthma; bronchodilators; contractility; spasmogens